IL17A and rheumatoid arthritis: The difference cannot be attributed either to different therapies administered to the two subgroups: patients with AS were treated mainly with anti-IL12, IL17, IL23, and anti-TNF-α whereas patients with RA were treated mostly with MTX, corticosteroids, anti-TNF-α, anti-IL6, JAKi, abatacept, and rituximab.